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Abstract
Background:  The R952Q variant in the low density lipoprotein receptor-related protein 8
(LRP8)/apolipoprotein E receptor 2 (ApoER2) gene has been recently associated with familial and
premature myocardial infarction (MI) by means of genome-wide linkage scan/association studies.
We were interested in the possible interaction of the R952Q variant with another established
cardiovascular genetic risk factor belonging to the same pathway, namely apolipoprotein E (APOE)
ε2/ε3/ε4 genotype, in modulating apolipoprotein E (ApoE) plasma levels and risk of MI.
Methods: In the Italian cohort used to confirm the association of the R952Q variant with MI, we
assessed lipid profile, apolipoprotein concentrations, and APOE ε2/ε3/ε4 genotype. Complete data
were available for a total of 681 subjects in a case-control setting (287 controls and 394 patients
with MI).
Results: Plasma ApoE levels decreased progressively across R952Q genotypes (mean levels ± SD
= RR: 0.045 ± 0.020, RQ: 0.044 ± 0.014, QQ: 0.040 ± 0.008 g/l; P for trend = 0.047). Combination
with APOE genotypes revealed an additive effect on ApoE levels, with the highest level observed
in RR/non-carriers of the E4 allele (0.046 ± 0.021 g/l), and the lowest level in QQ/E4 carriers (0.035
± 0.009 g/l; P for trend = 0.010). QQ/E4 was also the combined genotype with the most significant
association with MI (OR 3.88 with 95%CI 1.08–13.9 as compared with RR/non-carriers E4).
Conclusion: Our data suggest that LRP8 R952Q variant may have an additive effect to APOE ε2/
ε3/ε4 genotype in determining ApoE concentrations and risk of MI in an Italian population.
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Background
A genome-wide linkage scan in combination with case
control association analysis has become an effective strat-
egy for studying the genetics of complex diseases because
it is an unbiased approach without a priori hypothesis to
identify susceptibility genes. The low density lipoprotein
receptor-related protein 8 (LRP8) gene, located on chro-
mosome 1p34-36 [1], is an example of successful use of
this type of approach in discovering genes for coronary
artery disease (CAD) and myocardial infarction (MI). The
rs5174 polymorphism of LRP8 gene, coding for the non-
conservative substitution R952Q, has been associated
with familial CAD and MI in different independent popu-
lations [2], but not in sporadic MI populations [2,3]. The
LRP8 protein is a lipoprotein receptor belonging to the
low-density lipoprotein receptor (LDLR) family, and
expressed in several different cells and tissues, e.g. brain,
testes, heart, endothelial cells, smooth muscle cells, and
platelets [4].
LRP8 is also known as apolipoprotein E receptor 2
(ApoER2) [5]. Apolipoprotein E (ApoE) is the main lig-
and for receptor-mediated clearance of VLDLs and chy-
lomicron remnants, thus contributing to modulation of
plasma levels of lipoproteins, cholesterol and triglycerides
(TG) [6]. Among several proposed susceptibility genes for
CAD/MI, the apolipoprotein E (APOE located on chromo-
some 19q13.2) gene was one of the few survivors, as
recently confirmed by a meta-analyses involving thou-
sands of subjects [7]. Two common APOE polymor-
phisms (Cys112Arg and Arg158Cys) define the APOE ε2/ε3/
ε4 variants (APOE2 or ε2 = Cys112/Cys158; APOE3 or ε3:
Cys112/Arg158; APOE4 or ε4 = Arg112/Arg158), and have
been demonstrated to modulate cardiovascular risk [8].
This may occur either directly through modulation of
plasma levels of ApoE, which may be involved in athero-
genesis per se, and/or through modulation of plasma lipid
profile because of the different ApoE receptor-binding
affinities of the three isoforms (APOE4>APOE3>APOE2)
[6]. Consequently, APOE4 is generally associated with
lower levels of ApoE and higher levels of ApoB and cho-
lesterol, as well as with an increased cardiovascular risk
[7,9,10].
In light of the common pathway shared by APOE and
LRP8/APOER2 genes, we were interested in investigating
the possible combined effect of LRP8 R952Q and APOE
ε2/ε3/ε4 variants in influencing ApoE levels and/or cardi-
ovascular risk. This hypothesis was tested by a case-con-
trol association study design within the cohort of the
Verona Heart Study (VHS).
Methods
Study Population
The VHS is an ongoing study aimed to identify new risk
factors for CAD and MI in a population of subjects with
documented angiographic data on coronary vessels.
Details about the enrolment criteria have been described
previously [11]. In the present study, we examined the
genotyping data on LRP8 and APOE from the cohort of
subjects previously used to replicate the association of
LRP8 R952Q with cardiovascular risk [2]. Within this
cohort (n = 724) we analysed APOE genotypes and the
plasma concentration of ApoE, as well as the plasma lipid
profile. A total of 681 subjects, enrolled between May
1996 and March 2000, for whom complete analyses were
available, were included in this study. Of these, 394 had
angiographically documented severe coronary atheroscle-
rosis (being candidates to coronary artery bypass grafting)
and a history of previous MI (MI group), documented by
combining data from clinical history with a thorough
review of medical records showing diagnostic electrocar-
diogram and enzyme changes, and/or the typical sequelae
of MI on ventricular angiography. Two hundred eighty-
seven subjects with completely normal coronary arteries,
being evaluated by coronary angiography for reasons
other than CAD (mainly valvular heart disease) were con-
sidered as controls (CAD-free group). Controls were also
required to have neither history nor clinical or instrumen-
tal evidence of atherosclerosis in vascular districts beyond
the coronary bed. At the time of blood sampling, a com-
plete clinical history was collected, including the assess-
ment of cardiovascular risk factors such as obesity,
smoking, hypertension and diabetes, as well as medica-
tion and therapy.
The study was approved by the local Ethical Committee.
Informed consent was obtained from all the subjects after
a full explanation of the study.
Biochemical analysis
Samples of venous blood were drawn from each subject
after an overnight fast. Serum lipids and the other com-
mon biochemical parameters were determined by routine
methods. LDL levels were estimated by means of the
Friedewald equation. ApoA1, ApoB and ApoE were meas-
ured by commercially available nephelometric immu-
noassays; antisera, calibrators and the BNII nephelometer
were from Dade Behring. ApoC-III was measured by a
fully automated turbidimetric immunoassay as previously
described [12]. The reagents were obtained from Wako
Pure Chemical Industries, and the procedure recom-
mended by the manufacturer was implemented on a RxL
Dimension Analyzer (Dade International Inc.).
Genotyping of polymorphisms
Genomic DNA was extracted from whole blood samples
by the phenol-chloroform procedure. For LRP8 R952Q
polymorphism, high-throughput SNP genotyping wasBMC Medical Genetics 2009, 10:41 http://www.biomedcentral.com/1471-2350/10/41
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performed using the 5' nuclease allelic discrimination
assay (TaqMan Assay) on an ABI PRISM 7900HT
Sequence Detection System as previously described [2].
APOE ε2/ε3/ε4 variants were genotyped according to a
previously described multilocus assay [13], except for the
use of a simplified PCR protocol to improve APOE geno-
typing, which was validated by RFLP and sequencing.
Briefly, each sample was amplified by two 33-cycle multi-
plex polymerase chain reactions (PCR, 32 ng of genomic
DNA each) and the PCR products were then hybridized to
an array of immobilised, sequence-specific oligonucle-
otide probes. The colorimetric detection was based upon
streptavidin-horseradish peroxidase.
Statistical analysis
All statistical analyses were performed with SPSS 14.0 sta-
tistical package (SPSS Inc., Chicago, IL). Distributions of
continuous variables in groups were expressed as means ±
standard deviation. Logarithmic transformation was per-
formed on all skewed variables, including TG, ApoC-III
and ApoE. Therefore, the statistical differences concerning
these parameters were also computed on the correspond-
ing log-transformed values, although, for the sake of clear-
ness, non-transformed data were reported in the Results.
Quantitative data were assessed using the Student's t-test
or by ANOVA with polynomial contrasts for linear trend
when indicated. Associations between qualitative varia-
bles were analyzed with the χ2-test, and linear trend anal-
ysis when indicated. The frequencies of the LRP8 and
APOE genotypes were compared with the values predicted
on the basis of the Hardy-Weinberg equilibrium by χ2-
test. To avoid an excessive subfractioning of the study
population in the analysis of combined genotypes (LRP8
R952Q stratified for APOE ε2/ε3/ε4 polymorphism),
APOE genotype stratification was simplified by consider-
ing two main groups, i.e. carriers E4 and non-carriers E4.
Moreover, a linear regression model estimating standard-
ized beta-coefficients was performed to assess the role of
LRP8 and APOE genotype as independent determinants
of serum ApoE levels. A value of P < 0.05 was considered
significant.
To assess the extent to which genetic polymorphisms were
associated with MI, odds ratios with 95% CIs were esti-
mated by univariate logistic regression analysis. Adjust-
ment for classical cardiovascular risk factors (i.e. sex, age,
hypertension, smoke, diabetes, cholesterol and triglycer-
ide) was performed by adding those covariates in a multi-
ple logistic-regression model. Analyses of potential
interactions between LRP8 R952Q and APOE ε2/ε3/ε4
variants in determining ApoE levels and MI risk were per-
formed by means of linear and logistic regression, respec-
tively.
Results
The general characteristics of the study population con-
sisting of controls and MI patients are summarized in
Table 1. As expected, the classical cardiovascular risk fac-
tors were more represented among MI patients. As previ-
ously reported, the R952Q variant was associated with MI,
with homozygous carriers of Q allele showing a near two-
fold increased risk (QQ versus RR homozygotes: OR = 1.92
with 95% CIs 1.19–3.12 by univariate analysis, and OR =
1.83 with 95% CIs 1.003–3.34 by multiple logistic regres-
sion after adjustment for classical cardiovascular risk fac-
tors, i.e. sex, age, hypertension, smoke, diabetes,
cholesterol and triglycerides). On the other hand, APOE4
variant was slightly – but not significantly – more repre-
sented among MI patients (OR 1.39 with 95%CI 0.92–2.1
for carriers E4 versus non-carriers E4).
To assess the relation between genotypes and lipid profile
without potential confounding factors, we excluded from
the analysis subjects with diabetes (known to be associ-
ated with high levels of triglyceride-rich lipoproteins) or
those taking lipid-lowering drugs. In this subgroup (n =
449), the ApoE plasma concentration decreased progres-
sively across R952Q genotypes from "wild-type" RR
homozygotes to QQ homozygotes (RR: 0.045 ± 0.020,
RQ: 0.044 ± 0.014, QQ: 0.040 ± 0.008 g/l; P for trend =
0.047; Table 2). As expected, APOE ε2/ε3/ε4 genotype was
confirmed as an important determinant of lipid profile,
strongly influencing plasma ApoE, ApoB, total and LDL-
cholesterol plasma concentrations (Table 3). In a linear
regression analysis, both LRP8 and APOE genotype were
independent predictors of ApoE levels also after adjust-
ment for disease status, (standardized beta-coefficient = -
0.095, P = 0.049, and -0.123, P = 0.011, respectively).
When analyzed in combination, we found an additive
effect of LRP8 and APOE variants in determining the
plasma ApoE concentration, with a progressive decrease
from the highest level in RR/non-carriers E4 to the lowest
level in QQ/carriers E4 (P for trend = 0.010; Figure 1).
More precisely, the interaction between LRP8 and APOE
variants was not significant by regression analysis (P =
0.566), suggesting a reciprocally independent influence
on ApoE levels of the 2 polymorphisms that act additively
in determining the plasma ApoE concentration (i.e. the
presence of one genotype does not influence the effect of
the other on ApoE levels). On the other hand, no additive
effect or interaction between the two gene variants was
found with respect to other parameters of lipid profile
(data not shown).
In the whole study population, there was also an additive
effect of LRP8 and APOE variants on the risk of MI (P =
0.007 by χ2-test for linear trend), i.e. with the highest risk
in QQ/carriers E4 (OR 3.88 with 95%CI 1.08–13.9 as
compared with RR/non-carriers E4 – Figure 2). This asso-BMC Medical Genetics 2009, 10:41 http://www.biomedcentral.com/1471-2350/10/41
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ciation with MI remained significant even after adjust-
ment for age and sex (OR 4.19 with 95%CI 1.13–15.6),
whereas the statistical significance was marginally lost in
a regression adjusted for all the traditional atherosclerosis
risk factors (OR 3.84 with 95%CI 0.80–18.6). Similarly
with the previous analysis, the interaction was not signif-
icant by regression analysis (P = 0.739), suggesting that
the two polymorphisms act additively also in determining
the risk of MI.
Discussion
The LRP8 variant R952Q variant has been associated with
an increased risk of CAD. Previously we reported that the
R952Q variant was associated with increased platelet
aggregation, which may be through increased phosphor-
ylation of p38 mitogen-activated protein kinase (MAPK),
providing a possible functional explanation for increased
vascular risk [2]. Moreover, recent studies have confirmed
a role of LRP8 in platelet activation through modulation
of signal transduction of some ligands, like protein C, acti-
vated protein C and dimeric form of β 2-glycoprotein I
[14,15]. On the other hand, the results of the present
study suggest that, in addition to the previously demon-
strated platelet hyperaggregation [2], the LRP8/APOER2
R952Q variant may influence the cardiovascular risk also
through modulation of the ApoE pathway, particularly in
Table 1: General characteristics of the study population with myocardial infarction (MI) and controls
Characteristics Controlsa
(n = 287)
MIa
(n = 394)
P
Age (years) 58.1 ± 12.6 59.9 ± 10.0 0.048 *
Male sex (%) 69.0 84.0 <0.001 #
BMI (kg/m2) 25.3 ± 3.4 26.6 ± 3.3 <0.001 *
Hypertension (%) 34.3 62.4 <0.001 #
Smoking (%) 44.9 70.8 <0.001 #
Diabetes (%) 6.2 16.2 <0.001 #
Total cholesterol (mmol/L) 5.54 ± 1.08 5.80 ± 1.17 0.005 *
LDL-cholesterol (mmol/L) 3.58 ± 0.95 3.94 ± 0.99 <0.001 *
HDL-cholesterol (mmol/L) 1.42 ± 0.40 1.19 ± 0.29 <0.001 *
Triglycerides (mmol/L) 1.51 ± 0.67 1.99 ± 1.09 <0.001 *
Apo A-I (g/l) 1.42 ± 0.27 1.28 ± 0.22 <0.001 *
Apo B (g/l) 1.08 ± 0.26 1.23 ± 0.31 <0.001 *
Apo C-III (mg/dl) 10.8 ± 3.2 12.2 ± 4.6 <0.001 *
ApoE (g/l) 0.043 ± 0.014 0.046 ± 0.023 0.107
LRP8 R952Q polymorphism (%)
RR 43.9 38.1
RQ 45.3 43.9 0.027 #
QQ 10.8 18.0
APOE ε2/ε3/ε4 polymorphism (%)
carrier E2 8.7 8.6
E3/E3 76.7 72.1 0.280 #
carrier E4 14.6 19.3
a Only 681 subjects with complete analyses of LRP8 R962Q genotypes, APOE genotypes, and the ApoE plasma concentration were included.
*: by t-test
#: by χ2-test
Table 2: Lipid profile according to LRP8 R952Q in non-diabetic subjects without lipid-lowering therapy (n = 449)
LRP8 R952Q variant RR
(n = 190)
RQ
(n = 193)
QQ
(n = 66)
P *
Total cholesterol (mmol/l) 5.63 ± 1.10 5.90 ± 1.15 5.68 ± 0.90 0.774
LDL-cholesterol (mmol/l) 3.75 ± 0.98 3.92 ± 1.02 3.84 ± 0.80 0.546
HDL-cholesterol (mmol/l) 1.30 ± 0.37 1.36 ± 0.39 1.27 ± 0.37 0.643
Triglyceride (mmol/l) 1.63 ± 0.83 1.74 ± 0.86 1.70 ± 0.92 0.530
Apo A-I (g/l) 1.34 ± 0.25 1.36 ± 0.26 1.31 ± 0.25 0.426
Apo B (g/l) 1.13 ± 0.29 1.18 ± 0.27 1.17 ± 0.32 0.129
Apo C-III (mg/dl) 10.9 ± 3.2 11.5 ± 3.8 11.1 ± 3.7 0.825
ApoE (g/l) 0.045 ± 0.020 0.044 ± 0.014 0.040 ± 0.008 0.047
*: by ANOVA with polynomial contrasts for linear trendBMC Medical Genetics 2009, 10:41 http://www.biomedcentral.com/1471-2350/10/41
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combination with another genetic variant in the same
pathway, APOE ε2/ε3/ε4. These two genetic variants may
have an additive effect on both ApoE concentrations and
the risk of MI.
With respect to the modulation of circulating ApoE levels,
some lines of evidence support the biological plausibility
of the interaction between the two genetic variants. LRP8/
APOER2 protein is in fact not only an important modula-
tor of platelet signalling [16], but also a lipoprotein recep-
tor, with five functional domains closely related to those
of LDL- and VLDL-receptors. Notwithstanding these simi-
larities, ApoER2 appears to bind with high affinity only to
ApoE-rich β-VLDL, while affinity for LDL and other VLDL
Table 3: Lipid profile according to APOE ε2/ε3/ε4 polymorphism in non-diabetic subjects without lipid-lowering therapy (n = 449)
APOE ε2/ε3/ε4 variant Carrier E2
(n = 41)
E3/E3
(n = 333)
Carrier E4
(n = 75)
P *
Total cholesterol (mmol/l) 5.40 ± 1.18 5.73 ± 1.08 6.01 ± 1.10 0.005
LDL-cholesterol (mmol/l) 3.34 ± 0.85 3.85 ± 0.97 4.03 ± 0.96 0.002
HDL-cholesterol (mmol/l) 1.34 ± 0.37 1.31 ± 0.37 1.37 ± 0.45 0.457
Triglyceride (mmol/l) 1.97 ± 1.36 1.65 ± 0.76 1.69 ± 0.91 0.562
Apo A-I (g/l) 1.36 ± 0.25 1.34 ± 0.25 1.36 ± 0.25 0.976
Apo B (g/l) 0.98 ± 0.31 1.16 ± 0.28 1.24 ± 0.28 <0.001
Apo C-III (mg/dl) 12.7 ± 5.7 11.0 ± 3.3 11.1 ± 2.9 0.307
ApoE (g/l) 0.067 ± 0.037 0.042 ± 0.010 0.039 ± 0.011 <0.001
*: by ANOVA with polynomial contrasts for linear trend
Additive effect of LRP8 R952Q and APOE ε2/ε3/ε4 polymorphisms in determining plasma ApoE levels in non-diabetic subjects  without lipid-lowering therapy (n = 449) Figure 1
Additive effect of LRP8 R952Q and APOE ε2/ε3/ε4 polymorphisms in determining plasma ApoE levels in non-
diabetic subjects without lipid-lowering therapy (n = 449).
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is much lower [5]. The binding leads to internalization of
ApoE containing lipid vesicles [17], and thus it is conceiv-
able that functional genetic variants of LRP8/APOER2
may contribute to modulation of ApoE levels. The R952Q
variant has been already shown to be a "gain-of-function"
variant since it was associated with increased phosphor-
ylation of p38 MAPK in platelets stimulated by oxidized
LDL [2]. Indeed, we found a limited and specific influence
of the R952Q variant on the ApoE plasma concentration,
with lower levels in QQ homozygotes. It is tempting to
speculate that the glutamine to arginine substitution at
position 952 may also increase internalization of ApoE by
modifying the receptor-affinity for ApoE, but further bio-
chemical studies are needed to verify this hypothesis. No
significant association was found between the R952Q var-
iant and other lipid parameters, consistent with the elec-
tive affinity of LRP8/APOER2 for ApoE.
On the other side of the receptor/ligand interaction, it is
of interest to note that the well-known APOE ε2/ε3/ε4
variant is known to modulate the affinity of the ApoE pro-
tein for lipoprotein receptors. Remarkably, APOE4, the
isoform with the highest binding affinity for lipoprotein
receptors, has been associated with the lowest ApoE
plasma concentration [6]. Thus, the lowest ApoE levels we
found in subjects carrying the compound genotype
APOER2-952QQ/APOE4 is in accordance with the possi-
bility of the additive combination of a high-affinity ligand
with a receptor with high internalization activity.
Interestingly, in our study population the two genetic var-
iants of the ApoE pathway showed an additive effect also
in terms of association with the risk of MI, which
increased progressively with the highest OR in carriers
with combined APOER2-952QQ/APOE4. The APOE4
variant is indeed one of the few alleles of candidate genes
which has been consistently confirmed to be a risk factor
of CAD/MI, particularly through comprehensive meta-
analyses involving thousands of subjects [7,9,10]. In the
present study, E4 carriers were marginally more repre-
sented in MI patients without reaching statistical signifi-
cance probably because of the relatively small sample size.
The increased cardiovascular risk of APOE4 variant is gen-
erally considered to be a consequence of high LDL-choles-
terol level [6]. However, some findings challenge this
interpretation as the sole explanation of APOE genotype-
associated atherogenic risk. In a prospective study, the
increased risk of cardiovascular events in E4 carriers has
Risk of MI in relation to LRP8 R952Q and APOE ε2/ε3/ε4 polymorphisms in the whole study population (n = 681) Figure 2
Risk of MI in relation to LRP8 R952Q and APOE ε2/ε3/ε4 polymorphisms in the whole study population (n = 
681). RR/non-carriers E4 are considered as reference group for calculating OR.
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been found to be unrelated to their cholesterol level [18].
Besides its involvement in the clearance of VLDLs and
chylomicron remnants, ApoE has been implicated in
other functions with potential anti-atherogenic proper-
ties, such as regulation of vascular smooth muscle cell
proliferation, inhibition of platelet aggregation, anti-oxi-
dant properties, anti-inflammatory activity, and regula-
tion of immune response [6]. Based on these findings, it
has been proposed that low ApoE levels may represent a
cardiovascular risk factor per se (e.g., independent of
plasma lipids) [19]. Though this hypothesis is not univer-
sally accepted [20], it may explain the particularly
increased risk of MI found in carriers with combined
APOER2-952QQ/APOE4, i.e. in subjects genetically pre-
disposed to the lowest ApoE levels. On the other hand, in
the current study there was no significant difference of
ApoE concentrations between MI patients and controls.
This apparent paradox may be, at least in part, explained
by the fact that ApoE is localized on VLDLs and chylomi-
cron remnants. Thus, ApoE plasma levels may also be a
surrogate for plasma levels of the atherogenic triglyceride-
rich and remnants lipoprotein particles [19,20].
Conclusion
Our data suggest that LRP8 R952Q variant may have an
additive effect to APOE ε2/ε3/ε4 genotype in determining
plasma ApoE concentrations and the risk of MI in an Ital-
ian population. This study suffers from common limita-
tions of genetic association studies of complex traits,
particularly with a relatively small sample size. For exam-
ple, the loss of significance in the last regression model
about the risk of MI seems likely to be due to the small
sample size of the subgroup analysis. Noteworthy, there
was not a substantial decrease of the OR value, but rather
a widened CI range [21]. Nevertheless, our finding repre-
sents a hypothesis-generating example of a gene-gene
additive effect in the same metabolic pathway that war-
rants further future replications to assess the combined
effects of APOER2/APOE variants on modulation of the
risk of MI.
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